Abiopharma

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Recurrent Energy Secures $695 Million in Project Financing for 330 MW California Solar Project

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

SS&C GlobeOp Hedge Fund Performance Index and Capital Movement Index

Xanadu and University of Alberta Partner to Accelerate Pharmaceutical Discoveries with Quantum Computing

E-STORAGEs KuBank 3.0 for C&I Applications Successfully Passes Large-Scale Fire Testing

ProQR Announces Second Quarter 2026 Operating and Financial Results

General Announcement: 1H2026 Results Briefing